by Raynovich Rod | Mar 13, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
March 17 Update -GREEN DAY with Geopolitical risk on back burner As of 11.38a EDT Industrials lead up 1%, healthcare up 0.8%, IBB up 1.33% Biopharmaceuticals stocks were strong with Rayno large cap picks: Alexion (ALXN $117) up 1.45%, Amgen (AMGN $125) up 1.9%,...
by Raynovich Rod | Feb 25, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Biotech May Be A Bubble-But What to Do? The blogosphere is trying to temper bullish sentiment with a lot of “bubble “talk even though the cable channels are still pumping biotech. If you have been around biotech for 25 years especially during the last...
by Raynovich Rod | Feb 18, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 2/21: Life Science stocks have blown through new highs this AM Large and mid-cap biopharma: ALKS BIIB,PCYC,REGN SGEN etc ETFs: IBB ($270) and XBI ($165) at new highs Two Rayno Dx laggard stocks on the move: RGDX and VRML. ———- Rayno Life...
by Raynovich Rod | Feb 9, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Life Science Stocks Surge Ahead From February Lows NASDAQ Up 1.67%, IBB Up 4%, FBIOX up 4.72%, XBI up 5.64%, XLV up 1.7% The soaring biotech sector would not let a losing week go by and took off early Friday erasing most losses for the week 2/3 to 2/7. Institutions...
by Raynovich Rod | Jan 16, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Biotech Rally Continues With IBB ($245) At New Highs-Up 10 Pts. From Monday’s Bottom Several Rayno Life Science picks were up after presentations at the 2014 J.P.Morgan Healthcare Conference. All of our portfolio picks are strong holds unless otherwise noted....
by Raynovich Rod | Jan 10, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market Enters The Bubblet Phase in Early 2014 (Published in Seeking Alpha on January 9) Buyers Anticipating J.P. Morgan Conference: IBB up 3.79% YTD Last week we started a series of articles that will follow key technical and fundamental trends in the...
by Raynovich Rod | Dec 24, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Rayno Life Science Stock Picks Beat The Market Everybody now knows about the bull market in biotech stocks. Innovative products, favorable clinical news, M&A (see below) and breakthrough genomic technologies and targeted therapies have driven most life science...
by Raynovich Rod | Nov 22, 2013 | 2024 Rayno Biopharmaceuticals Portfolio
Large Cap Biotechs Rocketing Up:BIIB, GILD Despite a flattish Dow and S&P, many life science stocks are surging ahead. There are many movers in the Rayno Biopharmaceutical Portfolio : Biogen Idec BIIB $277) up 10%, Gilead (GILD $74.40) up 3.88% and Regeneron (REGN...
by Raynovich Rod | Nov 21, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Another Strong Day in Life Science Stocks Carl Icahn, activist investor takes a 13% stake in Hologic. Hologic (HOLX $22.82) was added to our portfolio on 4/9/13 but has been a laggard due to earnings misses. The stock is up 2.4% on a volume of 25M shares. Many stocks...
by Raynovich Rod | Nov 14, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Rayno Diagnostics and Tools Focus Stocks: 2013 Performance YTD A diversified life science portfolio must include clinical diagnostics and tools stocks because the synergies between therapy and diagnostics have never been stronger. Breakthroughs in molecular...